Q&A Genmab 2021-05-17
Aktiesnakken
Genmab
Zealand Pharma
NOVO
Shipping
Bavarian Nordic
Amerikanske aktier
Chemometec
TESLA
Biotek-snakken
AMBU
Gubra
ExpreS2ion
Grønne Aktier
Hansa Biopharma
Laks
Smallcap og First North aktier
EL-BILER
Medico
Pharma
Banker og Finans
Krypto
BITCOIN
Ennogie
Vestas
17/5 15:01 af Jan Van de Winkel |
In January, Janssen's DARZALEX FASPRO became the first and only FDA-approved treatment for AL amyloidosis..
| |
17/5 15:01 af Jan Van de Winkel |
During the first quarter of 2021, there were significant events for both DARZALEX and Kesimpta..
| |
17/5 15:00 af Jan Van de Winkel |
Recent highlights include the US FDA's acceptance of the tisotumab vedotin BLA for priority review based on the innovaTV 204 Phase II study. If approved, tisotumab vedotin would be a first-in-class therapy, and we believe that it has the potential to become an important treatment option for patients with recurrent or metastatic cervical cancer. The PDUFA target date for a potential U.S. FDA approval is October of this year..
| |
17/5 15:00 af Helge Larsen/PI-redaktør |
Can you give us a short-term update on the financial highlights and the key achievements in Q1?
| |
17/5 14:59 af Jan Van de Winkel |
Thank you for having us back to discuss Genmab’s results for Q1 2021. We look forward to yet another inspiring session with clever questions and energizing interaction as always.
| |
17/5 14:59 af Helge Larsen/PI-redaktør |
Good afternoon Jan van de Winkel. Welcome to Q&A here on ProInvestor.com. We are very happy to have you back here and ready to answer questions from our investors.
| |
17/5 14:59 af Jan Van de Winkel |
Yes,we are here and ready
| |
17/5 14:58 af Helge Larsen/PI-redaktør |
Hi Jan van de Winkel. Are you online?
| |
17/5 06:56 af Helge Larsen/PI-redaktør |
Denne Q&A starter kl. 15.
|